Schmitz Jörn E, Johnson R Paul, McClure Harold M, Manson Kelledy H, Wyand Michael S, Kuroda Marcelo J, Lifton Michelle A, Khunkhun Rajinder S, McEvers Kimberly J, Gillis Jacqueline, Piatak Michael, Lifson Jeffrey D, Grosschupff Gudrun, Racz Paul, Tenner-Racz Klara, Rieber E Peter, Kuus-Reichel Kristine, Gelman Rebecca S, Letvin Norman L, Montefiori David C, Ruprecht Ruth M, Desrosiers Ronald C, Reimann Keith A
Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, RE-113, 330 Brookline Ave., Boston, Massacusetts 02215, USA.
J Virol. 2005 Jul;79(13):8131-41. doi: 10.1128/JVI.79.13.8131-8141.2005.
Although live attenuated vaccines can provide potent protection against simian immunodeficiency virus (SIV) and simian-human immunodeficiency virus challenges, the specific immune responses that confer this protection have not been determined. To test whether cellular immune responses mediated by CD8+ lymphocytes contribute to this vaccine-induced protection, we depleted rhesus macaques vaccinated with the live attenuated virus SIVmac239Delta3 of CD8+ lymphocytes and then challenged them with SIVmac251 by the intravenous route. While vaccination did not prevent infection with the pathogenic challenge virus, the postchallenge levels of virus in the plasmas of vaccinated control animals were significantly lower than those for unvaccinated animals. The depletion of CD8+ lymphocytes at the time of challenge resulted in virus levels in the plasma that were intermediate between those of the vaccinated and unvaccinated controls, suggesting that CD8+ cell-mediated immune responses contributed to protection. Interestingly, at the time of challenge, animals expressing the Mamu-A01 major histocompatibility complex class I allele showed significantly higher frequencies of SIV-specific CD8+ T-cell responses and lower neutralizing antibody titers than those in Mamu-A01- animals. Consistent with these findings, the depletion of CD8+ lymphocytes abrogated vaccine-induced protection, as judged by the peak postchallenge viremia, to a greater extent in Mamu-A01+ than in Mamu-A01- animals. The partial control of postchallenge viremia after CD8+ lymphocyte depletion suggests that both humoral and cellular immune responses induced by live attenuated SIV vaccines can contribute to protection against a pathogenic challenge and that the relative contribution of each of these responses to protection may be genetically determined.
尽管减毒活疫苗能够有效抵御猿猴免疫缺陷病毒(SIV)和猿猴-人类免疫缺陷病毒的攻击,但其提供这种保护作用的具体免疫反应尚未明确。为了检测由CD8 +淋巴细胞介导的细胞免疫反应是否有助于这种疫苗诱导的保护作用,我们对接种减毒活病毒SIVmac239Delta3的恒河猴进行CD8 +淋巴细胞清除,然后通过静脉途径用SIVmac251对其进行攻击。虽然接种疫苗并不能预防致病性攻击病毒的感染,但接种疫苗的对照动物血浆中攻击后病毒水平明显低于未接种疫苗的动物。攻击时CD8 +淋巴细胞的清除导致血浆中的病毒水平处于接种疫苗和未接种疫苗对照动物之间,这表明CD8 +细胞介导的免疫反应有助于提供保护。有趣的是,在攻击时,表达Mamu-A01主要组织相容性复合体I类等位基因的动物比Mamu-A01阴性动物表现出更高频率的SIV特异性CD8 + T细胞反应和更低的中和抗体滴度。与这些发现一致,根据攻击后病毒血症峰值判断,CD8 +淋巴细胞的清除在Mamu-A01阳性动物中比在Mamu-A01阴性动物中更大程度地消除了疫苗诱导的保护作用。CD8 +淋巴细胞清除后对攻击后病毒血症的部分控制表明,减毒活SIV疫苗诱导的体液免疫和细胞免疫反应均可有助于抵御致病性攻击,并且这些反应对保护的相对贡献可能由基因决定。